Publications

Hong Y, Li HF, Romi F, Gilhus NE. HLA and MuSK-positive myasthenia gravis; a systematic review and meta-analysis. Acta Neurol Scand 2018;138:219-226.

Sanders DB, Wolfe GI, Narayanaswami P, Benatar M, Evoli A, Gilhus N, Illa I, Kuntz N, Massey J, Melms A, Murai H, Nicolle M, Palace J, Richman D, Verschuuren J. Developing treatment guidelines for myasthenia gravis. Ann NY Acad Sci, 2018;1412:95-101.

Gilhus NE. Eculizumab: a treatment option for myasthenia gravis? Lancet Neurol 2017;16:947-948.

Gilhus NE, Romi F, Hong Y, Skeie GO. Myasthenia gravis and infectious disease. J Neurol 2018;265:1251-1258.

Gilhus NE, Hong Y. Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence. 2018:in press.

Gilhus NE, Burns TM, Evoli A, Palace J, Tzartos S, Verschuuren JJGM, Myasthenia gravis. Nature Rev Dis Primers; 2018; invited manuscript.

Heldal AT, Gilhus NE. Epidemiology of myasthenia gravis. In: Oxford Textbook of Neurological and Neuropsychiatric Epidemiology. Eds. Brayne C, Feigin V, Launer L, Logroscino G. Oxford Univ. Press 2018, in press.

Gilhus NE. Myasthenia gravis and other immune-mediated disorders of the neuromuscular junction. In Neuroimmune Diseases; from Cells to the Living Brain. Eds Mitoma H, Manto M. Springer Nature. 2018; in press.

Hong Y, Zisimopoulou P, Trakas N, Karagiorgou K, Stergiou C, Skeie GO, Hao H-J, Gao X, Owe JF, Zhang X, Yue Y-X, Romi FR, Wang Q, Li H-F, Gilhus NE, Tzartos S. Multiple antibody detection in “seronegative” myasthenia gravis patients. Eur J Neurol 2017;24:844-850.

Hong Y, Skeie GO, Zisimopoulou P, Karagiorgou K, Tzartos SJ, Gao X, Yue Y-X, Romi F, Zhang X, Li H-F, Gilhus NE. Juvenile onset myasthenia gravis; autoantibody status, clinical characteristics and genetic polymorphisms,. J Neurol 2017;264:955-962.

Li HF, Hong Y, Zhang X, Xie Y, Skeie GO, Hao HJ, Gilhus NE, Liang B, Yue YX, Zhang HJ, Gao X, Wang Q, Ding XJ, Song M. Gene polymorphisms for both auto-antigen and immune-modulating proteins are associated with the susceptibility of autoimmune myasthenia gravis. Mol Neurobiol 2017;54:4771-4780.

Gilhus NE. Myasthenia gravis (letter). N Engl J Med 2017;376:e25.

Romi F, Hong Y, Gilhus NE. Pathophsiology and immunological profile of myasthenia gravis and its subgroups. Curr Opin Immunol 2017;49:9-13.

Gotaas HT, Skeie GO, Gilhus NE. Myasthenia gravis and amyotrophic lateral sclerosis;a pathogenic overlap. Neuromusc Dis 2016;26:337-341.

Hong Y, Li H-F, Skeie GO, Romi F, Hao H-J, Zhang X, Gao X, Owe JF, Gilhus NE. Autoantibody profile and clinical characteristics in a cohort of Chinese myasthenia gravis patients. J Neuroimmunol 2016;298:51-57.

Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S. Myasthenia gravis; autoantibody characteristics and their implications for therapy. Nature Rev Neurol 2016;12:259-268.

Stergiou C, Lazaridis K, …Gilhus NE,.. Tzartos SJ. Titin antibodies in “seronegative” myasthenia gravis; a new role for an old antigen. J Neuroimmunol 2016;292:108-115.

Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman D,  Verschuuren J, Narayanaswami P. International consensus guidance for management of myasthenia gravis. Neurology 2016;87:419-425.

Andersen JB, Gilhus NE, Sanders DB. Factors affecting outcome in myasthenia gravis.  Muscle Nerve 2016;54:1041-1049.

Gilhus NE, Kerty E, Løseth S, Mygland Å, Tallaksen C. Myasthenia gravis: diagnostikk og behandling. Tidsskr Nor Legeforen 2016;136:1089-1094.

Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification. Lancet Neurol 2016;15:357-358.

Gilhus NE. Myasthenia gravis. N Engl J Med 2016;375:2570-2581.

Gilhus NE. Neuromuscular junction disorders. In: Handbook of Neurological Therapy,    Oxford Univ. Press, New York 2015;177-186.

Nacu A, Andersen JP, Lisnic V, Owe JF, Gilhus NE. Complicating autoimmune diseases in myasthenia gravis; a review. Autoimmunity 2015;48:362-368.

Gilhus NE, Nacu A, Andersen JB, Owe JF. Myasthenia gravis and risks for comorbidity. Eur J Neurol 2015;22:17-23.

Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015;14:1023-1036.

Andersen JB, Heldal AT, Engeland A, Gilhus NE. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta Neurol Scand Suppl. 2014 Apr;(198):26-31. 

Andersen JB, Owe JF, Engeland A, Gilhus NE. Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study. Eur J Neurol. 2014 Jul;21(7):948-55.

Heldal AT, Eide GE, Romi F, Owe JF, Gilhus NE. Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development. PloSOne 2014;9:e114060:.

Wolff ASB, Owe J, Gilhus NE, Erichsen MM, Hapnes L, Kampe O, Meager A, Willcox N, Husebye ES. Clinical and serologic parallels to APS-I in patients with thymomas, and autoantigen transcripts in their tumors. J Immunol 2014;193:3890-3900.

Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE. EFNS/ENS guidelines for treatment of ocular myasthenia. Eur J Neurol 2014;21:687-693.

Gilhus NE.
Neuromuscular junction disorders.In: Handbook of Neurological Therapy,  Oxford Univ. Press 2013, in press.

Gilhus NE.
Advances in the treatment of myasthenia gravis.
Future Neurol 2012;7:701-708.

Romi F, Helgeland G, Gilhus NE.
Setum levels of matrix metalloproteinases; implications in clinical neurology.
Eur Neurol 2012;67:121-128.

Heldal AT, Eide GE, Gilhus NE, Romi F.
Geographical distribution of a national, seropositive myasthenia gravis population.
Muscle Nerve 2012;45:815-819.

Gilhus NE.
Myasthenia and neuromuscular junction.
Curr Opin Neurol 2012;25:523-529.

Romi F, Suzuki S, Suzuki N, Petzold A, Plant GB, Gilhus NE.
Anti voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis.
J Neurol 2012;259:1312-1316.

Maniaol A, Elsais A, Lorentzen ÅR…, Gilhus NE et al.
Late onset myasthenia gravis is associated with HLA-DRB1*15:01 in the Norwegian population.
PLoS One 2012;7:e36603:8p.

Hapnes L, Willcox N, Oftedal BE, Owe JF, Gilhus NE, Meager A, Husebye ES, Wolff AS.
Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups.
J Clin Immunol 2012;32:230-237.

Hoff JM, Loane M, Gilhus NE, Rasmussen S, Daltveit AK.
Arthrogryposis multiplexa congenita; an epidemiologic study of nearly 9 million births in 24 Eurocat registers.
Eur J Obst Gynecol Reprod Biol 2011;159:347-350.

Gilhus NE.
Lambert-Eaton myasthenic syndrome (LEMS); pathogenetic knowledge improves therapy.
Autoimune Diseases 2011;10:973808:5p.

Romi F, Helgeland G, Gilhus NE.
Heat shock proteins in clinical neurology.
Eur Neurol 2011;66:65-69

Luckman SP, Gilhus NE, Romi F.
Matrix metalloproteinase-3 in myasthenia gravis compared to other neurological disorders and healthy controls.
Autoimmune Diseases 2011;10:151258:4p.

Gilhus NE, Owe JP, Hoff JM, Romi F, Skeie GO, Aarli JA.
Myasthenia gravis; a review of available treatment approaches.
Autoimmune Diseases 2011;10:847393:8p.

Gilhus NE, Skeie GO, Romi F, Aarli JA.
Myasthenia gravis autoantibodies have a target also outside the neuromuscular junction.
Adv Clin Neur Rehab 2011;11:14-15.

Gilhus NE.
Acute treatment for myasthenia gravis.
Nature Rev Neurol 2011;7:132-134.

Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, Grisold W, Honnorat J,Sillevis Smitt PAE, Tanasescu R, Vedeler CA, Voltz R, Verschuuren JJGM.
Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.
Eur J Neurol 2011;18:19-27.

Helgeland G, Petzold A, Luckman SP, Gilhus NE, Plant GT, Romi FR.
Matrix metalloproteinases in myasthenia gravis.
Eur Neurol 2011;65:53-58.

Alseth EH, Maniaol AH, Elsais A, Nakkestad HL, Tallaksen C, Gilhus NE, Skeie GO.
Investigation for rapsyn and DOK-7 mutations in a cohort of seronegative myasthenia gravis patients.
Muscle Nerve 2011;43:574-577.

Willison HJ,Gilhus NE, Graus F, Jacobs BC, Liblau R, Vedeler C, Vincent A.
Use of antibody testing in nervous system disorders.
In: European Handbook of Neurological Management vol 1, 2^nd edition, Wiley-Blackwell 2011;75-80.

Skeie GO, Apostolski S, Evoli A, Gilhus NE, Harms L, Hilton-Jones D, Illa I, Melms A, Verschuuren J, Horge HW.
Autoimmune neuromuscular transmission disorders.
In: European Handbook of Neurological Management vol 1, 2^nd edition, Wiley-Blackwell 2011;321-331.

Andersen JB, Engeland A, Owe JF, Gilhus NE.
Myasthenia gravis requiring pyridostigmine treatment in a national population cohort.
Eur J Neurol 2010;17:1445-1450.

Helgeland G, Petzold A, Hoff JM, Gilhus NE, Plant G, Romi FR.
Anti-heat shock protein 70 antibody levels are increased in myasthenia gravis and Guillain Barré syndrome.
J Neuroimmunol 2010;22:180-183.

Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, Hilton-Jones D, Illa I, Melms A, Verschuuren J, Horge HW.
Guidelines for treatment of autoimmune neuromuscular transmission disorders.
Eur J Neurol 2010;17:893-902.

Verschuuren JJGM, Palace J, Gilhus NE.
Clinical aspects of myasthenia explained.
Autoimmunity 2010;43:1-9.

Owe JF, Cvancarova M, Romi F, Gilhus NE.
Extrathymic malignancies in thymoma patients with and without myasthenia gravis.
J Neurol Sci 2010;290:66-69.

Gilhus NE, Aarli JA.
Nevromuskulære transmisjonsforstyrrelser.
In: Nevrologi; fra barn til voksen, undersøkelse, diagnose og behandling. 5. utgave. Vett & Viten, Nesbru 2010;283-290.

Aarli JA, Gilhus NE,  Romi F, Skeie GO.
Myasthenia gravis in the elderly.
Aging Health 2009;5:561-568.

Alseth EH, Nakkestad HL, Aarseth J, Gilhus NE, Skeie GO.
Interleukin-10 promoter polymorphisms in myasthenia gravis.
J Neuroimmunol 2009;210:63-66.

Heldal AT, Owe J, Gilhus NE, Romi F.
Seropositive myasthenia gravis: a nationwide epidemiologic study.
Neurology 2009;73:150-151.

Gilhus NE.
Autoimmune myasthenia gravis.
Expert Rev Neurother 2009;9.351-358.

Gilhus NE.
Is it safe to use statins in patients with myasthenia gravis?
Nature Clin Pract Neurol 2009;5:8-9.

Owe JF, Gilhus NE.
Myasthenia gravis and the heart.
Adv Clin Neurosci Rehab 2008;8:9-10.

Owe JF, Davidsen ES, Eide GE, Gerdts E, Gilhus NE.
Left ventricular long-axis function in myasthenia gravis.
J Neurol 2008;255:1777-1784.

Helgeland G, Luckman SP, Romi FR, Jonassen AK, Gilhus NE.
Myasthenia gravis sera have no effect on cardiomyocytes in vitro.
J Neuroimmunol 2008;201-202:74-79.

Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, van Schaik IN, Scolding N, Soelberg Sørensen P, Udd B.
EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases.
Eur J Neurol 2008;15:893-908.

Aarli JA, Gilhus NE, Romi F, Skeie GO.
Titin and ryanodine receptor antibodies and neurmuscular involvement in myasthenia gravis.
Future Neurol 2008;3:87-92.

Romi FR, Gilhus NE, Luckman S.
Serum matriix metalloproteinase-3 levels are elvated in myasthenia gravis.
J Neuroimmunol 2008;195:96-99.

MacLennan C, Vincent A, Marx A, Willcox N, Gilhus NE, Newsom-Davis J, Beeson D.
Preferential expression of AChR epsilon subunit in thymomas from patients with myasthenia gravis.
J Neuroimmunol 2008;201-202:28-32.